9,768 Shares in Phreesia, Inc. (NYSE:PHR) Purchased by Raymond James & Associates

Raymond James & Associates acquired a new stake in shares of Phreesia, Inc. (NYSE:PHR) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 9,768 shares of the company’s stock, valued at approximately $226,000.

Other institutional investors also recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new stake in Phreesia during the third quarter valued at approximately $53,000. SG Americas Securities LLC bought a new position in shares of Phreesia in the third quarter valued at approximately $132,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Phreesia by 44.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,433 shares of the company’s stock valued at $214,000 after acquiring an additional 3,518 shares during the last quarter. Synovus Financial Corp raised its stake in shares of Phreesia by 45.7% in the third quarter. Synovus Financial Corp now owns 12,447 shares of the company’s stock valued at $233,000 after acquiring an additional 3,903 shares during the last quarter. Finally, Spouting Rock Asset Management LLC raised its stake in shares of Phreesia by 16.5% in the third quarter. Spouting Rock Asset Management LLC now owns 13,381 shares of the company’s stock valued at $250,000 after acquiring an additional 1,895 shares during the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Phreesia

In other news, SVP Amy Beth Vanduyn sold 3,354 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $22.62, for a total transaction of $75,867.48. Following the completion of the transaction, the senior vice president now directly owns 123,463 shares in the company, valued at approximately $2,792,733.06. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Chaim Indig sold 3,392 shares of the firm’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $22.86, for a total value of $77,541.12. Following the completion of the sale, the chief executive officer now directly owns 1,222,005 shares in the company, valued at approximately $27,935,034.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Amy Beth Vanduyn sold 3,354 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $22.62, for a total transaction of $75,867.48. Following the completion of the sale, the senior vice president now owns 123,463 shares of the company’s stock, valued at $2,792,733.06. The disclosure for this sale can be found here. Insiders sold a total of 82,989 shares of company stock worth $1,911,735 in the last three months. Insiders own 5.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on PHR shares. Truist Financial started coverage on shares of Phreesia in a research note on Monday, February 26th. They issued a “buy” rating and a $35.00 target price for the company. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research note on Friday, March 15th. Stephens reiterated an “overweight” rating and issued a $28.00 target price on shares of Phreesia in a research note on Friday, March 22nd. JMP Securities lifted their target price on shares of Phreesia from $28.00 to $30.00 and gave the company a “market outperform” rating in a research note on Thursday, March 21st. Finally, DA Davidson reaffirmed a “neutral” rating and set a $32.00 price objective on shares of Phreesia in a report on Friday, March 15th. Two analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, Phreesia has a consensus rating of “Moderate Buy” and a consensus target price of $31.62.

Phreesia Stock Performance

PHR stock opened at $20.74 on Wednesday. The business’s fifty day moving average is $23.43 and its 200-day moving average is $21.51. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.02. The company has a market cap of $1.17 billion, a P/E ratio of -8.23 and a beta of 0.92. Phreesia, Inc. has a twelve month low of $12.05 and a twelve month high of $34.98.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.02. The company had revenue of $95.00 million for the quarter, compared to the consensus estimate of $93.52 million. Phreesia had a negative return on equity of 53.33% and a negative net margin of 38.42%. The firm’s quarterly revenue was up 24.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.72) EPS. Equities research analysts forecast that Phreesia, Inc. will post -1.48 EPS for the current year.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.